Table 2.
Baseline demographic and clinical characteristic and clinical outcome in patients with localized GA.
| Time to recurrence | Overall Survival | ||||||
|---|---|---|---|---|---|---|---|
| N | Median time to recurrence, yrs (95% CI) |
Relative risk (95% CI) |
P value* | Median overall survival, yrs (95% CI) |
Relative risk (95% CI) |
P value* | |
| Age, years | 0.42 | 0.65 | |||||
| < 60 | 80 | 2.2 (1.5, 14.5+) | 1 | 4.7 (3.8, 14.6+) | 1 | ||
| ≥ 60 | 57 | 3.7 (2.1, 12.3+) | 0.81 (0.48, 1.36) | 4.5 (3.3, 7.3) | 1.14 (0.64, 2.05) | ||
| Sex | 0.85 | 0.32 | |||||
| Male | 83 | 2.3 (1.8, 7.0) | 1 | 4.1 (3.3, 7.3) | 1 | ||
| Female | 54 | 7.0 (1.5, 8.3+) | 0.95 (0.56, 1.63) | 7.3 (3.8, 8.3+) | 0.72 (0.37, 1.39) | ||
| Race | 0.085 | 0.040 | |||||
| White | 63 | 1.7 (1.2, 4.4) | 1 | 3.8 (2.7, 5.5) | 1 | ||
| African American | 1 | 0.5+ | — | 0.5+ | — | ||
| Asian | 28 | 7.0 (2.3, 14.5+) | 0.45 (0.23, 0.91) | 7.3 (3.3, 14.6+) | 0.45 (0.20, 1.03) | ||
| Hispanic | 45 | 3.7 (2.1, 10.7+) | 0.63 (0.34, 1.17) | 10.7+ (3.6, 10.7+) | 0.36 (0.15, 0.85) | ||
| Stage | 0.030 | ||||||
| I | 12 | 4.3+ (2.2, 4.3+) | 1 | 4.4+ | — | 0.32 | |
| II | 36 | 7.0 (2.9, 10.7+) | 1.56 (0.35, 6.98) | 5.4 (4.1, 10.7+) | 1 | ||
| III | 71 | 1.8 (1.4, 2.8) | 3.24 (0.78, 13.5) | 3.8 (2.8, 7.3) | 1.31 (0.69, 2.50) | ||
| IV | 18 | 1.6 (1.2, 3.8+) | 4.00 (0.86, 18.5) | 7.3+ (1.4, 7.3+) | 1.33 (0.43, 4.09) | ||
| Tumor stage | 0.013 | 0.30 | |||||
| T1 † | 4 | ||||||
| T2 † | 44 | 8.3+ (2.9, 8.3+) | 1 | 5.4 (4.1, 8.3+) | 1 | ||
| T3 ‡ | 79 | 1.7 (1.4, 4.4) | 2.04 (1.14, 3.67) | 4.5 (3.3, 7.3) | 1.40 (0.73, 2.68) | ||
| T4 ‡ | 10 | ||||||
| N | 0.004 | 0.088 | |||||
| Negative | 27 | 7.0 (1.8, 10.7+) | 1 | 7.3 (3.4, 10.7+) | 1 | ||
| N1 | 64 | 4.4 (2.2, 14.5+) | 0.99 (0.47, 2.11) | 5.5 (4.1, 14.6+) | 1.07 (0.46, 2.47) | ||
| N2 | 31 | 1.3 (1.1, 2.3) | 2.62 (1.15, 5.94) | 3.3 (2.0, 5.7+) | 2.27 (0.85, 6.07) | ||
| N3 | 15 | 1.6 (1.0, 3.8+) | 1.96 (0.73, 5.32) | 2.4 (1.1, 3.8+) | 2.35 (0.66, 8.41) | ||
| ECOG performance status | 0.77 | 0.25 | |||||
| 0 | 62 | 2.5 (1.7, 10.7+) | 1 | 4.5 (2.8, 10.7+) | 1 | ||
| 1 | 65 | 2.3 (1.6, 14.5+) | 1.00 (0.60, 1.68) | 5.7 (3.8, 14.6+) | 0.68 (0.37, 1.25) | ||
| 2 | 10 | 2.2+ (1.7, 2.2+) | 0.60 (0.14, 2.53) | 2.2+ (1.2, 2.2+) | 1.67 (0.36, 7.75) | ||
| Differentiation | 0.15 | 0.098 | |||||
| Moderate | 27 | 2.1 (1.1, 3.8+) | 1 | 4.1 (2.7, 4.7) | 1 | ||
| Poor/Moderate ‡ | 10 | 3.7 (2.1, 14.5+) | 0.65 (0.36, 1.19) | 7.3 (3.8, 14.6+) | 0.59 (0.31, 1.13) | ||
| Poor ‡ | 97 | ||||||
| Lauren | 0.87 | 0.74 | |||||
| Diffuse | 40 | 3.7 (1.8, 8.9+) | 1 | 7.3 (5.4, 8.9+) | 1 | ||
| Intestinal | 50 | 7.0 (2.1, 14.5+) | 0.87 (0.45, 1.67) | 5.7 (3.8, 14.6+) | 1.10 (0.48, 2.51) | ||
| Mixed | 21 | 12.3+ (1.7, 12.3+) | 1.04 (0.45, 2.41) | 3.6 (1.9, 12.3+) | 1.52 (0.51, 4.58) | ||
| Type of chemotherapy | 0.003 | 0.004 | |||||
| 5-FU/LV | 70 | 7.0 (2.8, 10.6+) | 1 | 7.3 (4.1, 10.6+) | 1 | ||
| 5-FU/LV/oxaliplatin | 19 | 1.6 (1.1, 2.9) | 2.66 (1.23, 5.76) | 2.4 (1.2, 4.5+) | 4.24 (1.69, 10.6) | ||
| 5-FU, cisplatin, CPT-11 | 25 | 1.7 (1.2, 14.5+) | 1.46 (0.71, 3.01) | 4.1 (2.2, 14.6+) | 1.36 (0.59, 3.12) | ||
| None | 23 | 2.1 (0.8, 2.5) | 2.80 (1.48, 5.27) | 4.5 (2.8, 5.5) | 2.27 (1.09, 4.74) | ||
| Radiation | 0.92 | 0.68 | |||||
| Yes | 88 | 2.5 (1.8, 14.5+) | 1 | 4.5 (3.3, 14.6+) | 1 | ||
| No | 48 | 3.7 (1.7, 12.3+) | 1.03 (0.60, 1.76) | 5.4 (3.8, 12.3+) | 0.89 (0.48, 1.63) | ||
*
Based on log-rank test
+
Estimates were not reached.
—
No events occurred and estimates were not obtained.
† ‡
Grouped together for the estimates of relative risk
Abbreviations: CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; yrs, years; 5-FU, 5-fluorouracil; LV, leucovorin; CPT11, Irinotecan; —, no events occurred and estimates were not obtained.